{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:38:46Z","timestamp":1794623926191,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI170159-01A1"],"award-info":[{"award-number":["R21AI170159-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijid.2023.11.029","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:23:29Z","timestamp":1700915009000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-0688","authenticated-orcid":false,"given":"Xueying","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bankole","family":"Olatosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.11.029_bib0001","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.11.029_bib0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.11.029_bib0003","doi-asserted-by":"crossref","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","article-title":"COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1\u2013April 30, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2023.11.029_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5018","article-title":"Trends in COVID-19 vaccine administration and effectiveness through October 2021","volume":"5","author":"Winkelman","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2023.11.029_bib0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijid.2023.11.029_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2119763","article-title":"Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis","volume":"18","author":"Yin","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2023.11.029_bib0007","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2023.11.029_bib0008","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2023.11.029_bib0009","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijid.2023.11.029_bib0010","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.11.029_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149125","article-title":"Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection","volume":"131","author":"Riou","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijid.2023.11.029_bib0012","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV","volume":"74","author":"Woldemeskel","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.11.029_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBiomedicine"},{"key":"10.1016\/j.ijid.2023.11.029_bib0014","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"Covid-19 vaccine immunogenicity in people living with HIV-1","volume":"40","author":"Nault","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.11.029_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101226","article-title":"Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study","volume":"43","author":"Feng","year":"2022","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ijid.2023.11.029_bib0016","doi-asserted-by":"crossref","unstructured":"Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, et\u00a0al. A retrospective analysis of COVID-19 mRNA vaccine breakthrough infections - risk factors and vaccine effectiveness. medRxiv 2021. http:\/\/dx.doi.org\/10.1101\/2021.10.05.21264583.","DOI":"10.1101\/2021.10.05.21264583"},{"key":"10.1016\/j.ijid.2023.11.029_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15934","article-title":"Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States","volume":"5","author":"Coburn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2023.11.029_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2023.11.029_bib0019","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0000000000003405","article-title":"Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV","volume":"36","author":"Chambers","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2023.11.029_bib0020","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/infdis\/jiab075","article-title":"Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection","volume":"223","author":"Tarhini","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2023.11.029_bib0021","unstructured":"Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID19 vaccines currently authorized in the United States, https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html; 2021 [accessed 08 October 2022]."},{"key":"10.1016\/j.ijid.2023.11.029_bib0022","article-title":"COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study","volume":"12","author":"Xueying","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijid.2023.11.029_bib0023","doi-asserted-by":"crossref","first-page":"812","DOI":"10.21037\/atm-20-3998","article-title":"Propensity score matching with R: conventional methods and new features","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijid.2023.11.029_bib0024","unstructured":"Counsil of state and territorial epidemiologists. Standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19), https:\/\/cdn.ymaws.com\/www.cste.org\/resource\/resmgr\/2020ps\/Interim-20-ID-01_COVID-19.pdf; 2020 [accessed 03 November 2022]."},{"key":"10.1016\/j.ijid.2023.11.029_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijid.2023.11.029_bib0026","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2022.10.005","article-title":"Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis","volume":"124","author":"Yin","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2023.11.029_bib0027","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.021","article-title":"Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination","volume":"83","author":"Butt","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2023.11.029_bib0028","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.vaccine.2023.02.038","article-title":"Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities","volume":"41","author":"Smits","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.11.029_bib0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/COH.0000000000000790","article-title":"The effect of HIV on COVID-19 vaccine responses","volume":"18","author":"Levy","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijid.2023.11.029_bib0030","article-title":"Efficacy of Covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223007907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223007907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T08:01:37Z","timestamp":1717315297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223007907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"alternative-id":["S1201971223007907"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.11.029","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}